RxDoctor Payments Data

Daniel Kambic, DO

Family Medicine · Steelton, PANPI 1487616991

Payments from drug & device makers

$20,190in general payments, 2019–2025

Across 1,214 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$2K
  • AbbVie$2K
  • Boehringer Ingelheim$2K
  • Lilly USA, LLC$1K
  • plus $8K from 47 others

What the payments were for

  • Food & beverage$20,152100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,190 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$149,468
Medicare patients
217
Services billed
2,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin148$181,956
Trelegy ElliptaFluticasone/Umeclidin/Vilanter150$172,872
OzempicSemaglutide88$118,829
EliquisApixaban89$74,137
JanuviaSitagliptin Phosphate45$51,982
FarxigaDapagliflozin Propanediol59$50,908
BiktarvyBictegrav/Emtricit/Tenofov Ala11$41,883
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog48$41,548
MounjaroTirzepatide27$28,233
Breo ElliptaFluticasone/Vilanterol49$27,028
TrulicityDulaglutide22$25,999
XareltoRivaroxaban20$24,626
Tresiba Flextouch U-200Insulin Degludec12$23,779
MyrbetriqMirabegron22$21,323
TradjentaLinagliptin12$17,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$2,045$208,365210 claims
Boehringer IngelheimJardiance, Tradjenta$1,935$199,225160 claims
Novo NordiskOzempic$2,313$118,82988 claims
PfizerEliquis$618$74,13789 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,217$57,57470 claims
Lilly USA, LLCMounjaro, Trulicity$1,395$54,23249 claims
MerckJanuvia$260$51,98245 claims
Johnson & JohnsonXarelto$453$24,62620 claims
Astellas Pharma US IncMyrbetriq$216$21,32322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Steelton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →